Horizon Discovery and Blueprint Medicines Enter Oncology Research Service Agreement
News Oct 08, 2013
Horizon will use its proprietary platform and expertise to screen a selection of Blueprint’s unique and highly selective kinase inhibitor tool compounds on a panel of 26 X-MAN isogenic cell lines. Performing screens on X-MAN cell lines will provide valuable insights into elucidating synthetic lethal interactions with approximately 100 kinase targets in various cancer subtypes.
Horizon provides definitive and controlled preclinical model systems through the use of isogenic cell lines, where the genetic modification of interest can be directly compared to its matched normal cell. These cell lines have been generated through the GENESIS™ genome editing platform, which now includes ZFN and CRISPR, as well as the company’s proprietary rAAV technology.
The use of panels of these isogenic cell lines allows molecularly-defined cellular models to be systematically profiled, thereby providing a powerful tool for the investigation of sensitivity and resistance to cancer therapeutics. Horizon has recently launched this as a service broadly available to academic and commercial customers.
Blueprint Medicines has developed a proprietary platform that combines genomics expertise with a novel library of kinase inhibitors to enable the rapid development of potent, highly selective compounds to address clear genomic driver targets.
Dr. Christoph Lengauer, Chief Scientific Officer at Blueprint Medicines, commented: “Horizon’s track record in precise genome engineering of patient relevant cell line models and expertise in the field of oncology provide the ideal resource to support Blueprint’s drive to develop genetically tailored, highly selective cancer therapies.”
Dr. Chris Torrance, Chief Scientific Officer at Horizon, said: “We are delighted that Blueprint has selected Horizon as a partner for its cancer targets discovery effort, and look forward to contributing to the search for novel drug targets through use of our drug discovery services."
Acquisition Sees Agilent Gain Powerful NGS IP PortfolioNews
Agilent Technologies announces its acquisition of the molecular and sample barcoding portfolios of Population Genetics Technologies.READ MORE
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
Big-Data Analysis Points Toward New Drug Discovery MethodNews
A research team has developed a computational method to systematically probe massive amounts of open-access data to discover new ways to use drugs, including some that have already been approved for other uses.
Comments | 0 ADD COMMENT
EMBL Course: Next Generation Sequencing: RNA Sequencing Library Preparation
Apr 23 - Apr 27, 2018
EMBO Practical Course: Microbial Metagenomics: A 360º Approach
Apr 23 - Apr 30, 2018